Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SHPG
Previous Symbol
CUSIPN/A
Phone353-1609-6000
Debt
Debt-to-Equity Ratio0.36
Current Ratio0.92
Quick Ratio0.51
Price-To-Earnings
Trailing P/E Ratio11.34
Forward P/E Ratio11.41
P/E Growth1.56
Sales & Book Value
Annual Sales$15.16 billion
Price / Sales3.47
Cash Flow$22.6592 per share
Price / Cash Flow7.60
Book Value$119.43 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins30.63%
Return on Equity12.70%
Return on Assets7.06%
Miscellaneous
Employees23,044
Outstanding Shares305,280,000
Market Cap$52.74 billion
OptionableOptionable
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire declared a dividend on Thursday, August 2nd. Stockholders of record on Friday, September 7th will be given a dividend of $0.168 per share on Friday, October 19th. The ex-dividend date is Thursday, September 6th. View Shire's Dividend History.
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $3.64 earnings per share for the quarter, missing the Zacks' consensus estimate of $3.65 by $0.01. The biopharmaceutical company earned $3.87 billion during the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The business's revenue was up 4.7% on a year-over-year basis. During the same period last year, the company posted $3.81 earnings per share. View Shire's Earnings History.
When is Shire's next earnings date?
What guidance has Shire issued on next quarter's earnings?
Shire updated its FY 2020 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.5-7.5 billion, compared to the consensus revenue estimate of $4.01 billion.Shire also updated its FY18 guidance to $14.77-15.37 EPS.
What price target have analysts set for SHPG?
14 equities research analysts have issued 1 year target prices for Shire's stock. Their predictions range from $150.00 to $237.00. On average, they expect Shire's stock price to reach $201.1111 in the next year. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for Shire.
What is the consensus analysts' recommendation for Shire?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.
What are Wall Street analysts saying about Shire stock?
Here are some recent quotes from research analysts about Shire stock:
- 1. According to Zacks Investment Research, "Shire’s sales and earnings missed estimates in third-quarter 2018. The company launched Takhzyro, the first monoclonal antibody to prevent hereditary angioedema attacks, in the United States. It also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use, recommending marketing authorization in Europe. Shire continues to pay its debt while advancing its late-stage pipeline. Takeda’s proposed acquisition of Shire will close in first half of 2019, subject to additional regulatory approvals. The company completed the sale of its Oncology franchise to Servier S.A.S. in August 2018. In September, it acquired sanaplasma AG, a source plasma collection company that adds 14 new centers in the Czech Republic and Hungary to Shire’s European-based plasma collection network. Moreover, the company’s shares have outperformed the industry year to date." (11/15/2018)
- 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
- 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)
Has Shire been receiving favorable news coverage?
News headlines about SHPG stock have trended positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Shire earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX) and Zoetis (ZTS).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Prof. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
Who are Shire's major shareholders?
Shire's stock is owned by many different of retail and institutional investors. Top institutional investors include Abrams Capital Management L.P. (0.74%), Third Point LLC (0.53%), Janus Henderson Group PLC (0.48%), Vanguard Group Inc. (0.43%), FMR LLC (0.40%) and PointState Capital LP (0.39%).
Which major investors are selling Shire stock?
SHPG stock was sold by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Janus Henderson Group PLC, Deutsche Bank AG, Morgan Stanley, SG Americas Securities LLC, Odey Asset Management Group Ltd, Hsbc Holdings PLC and FMR LLC.
Which major investors are buying Shire stock?
SHPG stock was bought by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Third Point LLC, PointState Capital LP, OZ Management LP, Kepos Capital LP, Numen Capital LLP, Credit Suisse AG and Marshall Wace LLP.
How do I buy shares of Shire?
Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire's stock price today?
One share of SHPG stock can currently be purchased for approximately $171.85.
How big of a company is Shire?
Shire has a market capitalization of $52.74 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (NASDAQ SHPG)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
